Sugammadex
- Generic Name
- Sugammadex
- Brand Names
- Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal
- Drug Type
- Small Molecule
- Chemical Formula
- C72H112O48S8
- CAS Number
- 343306-71-8
- Unique Ingredient Identifier
- 361LPM2T56
- Background
Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intuba...
- Indication
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.
- Associated Conditions
- Neuromuscular blockade caused by vecuronium bromide
- Associated Therapies
- -
Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 128
- Registration Number
- NCT01050543
Sugammadex and Neostigmine at Residual Neuromuscular Blockade
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 99
- Registration Number
- NCT01006720
- Locations
- 🇩🇪
Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München, Munic, Bavaria, Germany
Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 164
- Registration Number
- NCT00826176
Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 308
- Registration Number
- NCT00825812
Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 140
- Registration Number
- NCT00758485
Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 161
- Registration Number
- NCT00751179
Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 140
- Registration Number
- NCT00724932
Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00702715
Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00675792
Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00656799
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath